Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2

Diagnosis, Therapeutic Targets, and Molecular Mechanisms

1st Edition - April 1, 2022

Write a review

  • Editors: Ganji Nagaraju, Ramakrishna Vadde
  • Hardcover ISBN: 9780323988070
  • eBook ISBN: 9780323993654

Purchase options

Purchase options
Available
DRM-free (EPub, PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies. This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Key Features

  • Provides detailed information on traditional and novel diagnostic tools for hepatocellular carcinoma
  • Discusses promising targeted therapies, both available and in development, explaining the best option to use for specific cases
  • Brings recent findings in immunotherapies, immune checkpoint inhibitors and nanotechnology-based therapeutic approaches for treatment of HCC

Readership

Cancer researchers, oncologists. Medical doctors, hepathologists, graduate students

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Dedication
  • List of contributors
  • About the editors
  • Preface
  • Chapter 1. Hepatocellular carcinoma diagnosis
  • Abstract
  • Abbreviations
  • Introduction
  • Conflict of interest
  • Funding
  • References
  • Chapter 2. Computational analysis of prognosis-related genes in liver cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Materials and methods
  • Results
  • Discussion
  • Conclusion
  • References
  • Further reading
  • Chapter 3. Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma
  • Abstract
  • Introduction
  • Computational methods/approaches used for identification of biomarkers/pathways/enzymes in hepatocellular carcinoma
  • Conclusion
  • Acknowledgment
  • Conflict of interest
  • Funding
  • Abbreviations
  • References
  • Chapter 4. Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • RNA-sequencing technologies and applications in cancer
  • Transcriptomics in hepatocellular carcinoma
  • RNAseq analysis of the tumor microenvironment in hepatocellular carcinoma
  • Noncoding RNAs as biomarkers in hepatocellular carcinoma
  • Conclusion and future perspectives
  • Conflict of interest
  • References
  • Chapter 5. Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Mechanisms of viral hepatocellular pathogenicity
  • Nonviral risk factors associated with liver cancer formation
  • Stages of liver cancer and risk factors involved
  • Genetic profiling of hepatocellular carcinoma using next-generation sequencing
  • Deep Sequencing and whole-exome sequencing in unveiling the heterogeneity of hepatocellular carcinoma
  • Genome arrays in liver cancer screening
  • Prospects of next-generation sequencing findings leading to precision medicine/therapy
  • References
  • Chapter 6. Liver cancer: the tumor microenvironment and associated pathways
  • Abstract
  • Abbreviation
  • Introduction
  • Major risk factors for developing liver cancer
  • Influence of the tumor microenvironment
  • Molecular mechanisms
  • Associated pathways
  • Conclusion
  • References
  • Chapter 7. Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach
  • Abstract
  • Abbreviations
  • Introduction
  • Pathways to cause liver cancer
  • Computational approach
  • Microarray-based therapy
  • Identification of key genes
  • Protein-protein interaction
  • microRNA-based therapy
  • miRNA inhibition
  • Copy number variations study
  • Target therapy in liver cancer
  • Mathematical modeling
  • Ensemble modeling
  • Machine learning model
  • Genome-scale metabolic modeling
  • Epigenetic regulation
  • Conclusion
  • Conflict of interest
  • References
  • Chapter 8. Targeting ion channels in hepatic cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Ion channels
  • Ion channels in cancer pathophysiology
  • Ion channels in liver cancer
  • Diagnostic and prognostic value of ion channels and their subunits in hepatic cancer
  • Summary and future perspectives
  • Conflict of interest
  • References
  • Chapter 9. Tyrosine kinases: their role in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Treatment of hepatocellular carcinoma
  • Involvement of tyrosine kinases in liver cancer
  • Classification of tyrosine kinases
  • Small molecules as tyrosine kinase inhibitors that target receptor tyrosine kinase
  • Small molecules as tyrosine kinase inhibitors that target nonreceptor tyrosine kinase
  • Conclusion and future perspectives
  • References
  • Chapter 10. Role of transcription factors in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction to transcription factors
  • Hepatocellular carcinoma and transcription factor
  • Drugs targeting hepatocellular carcinoma and their mode of action
  • Conclusion and future perspectives
  • References
  • Chapter 11. Modulatory act of diverse transcriptional factors in liver carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Transcriptional regulation of activator protein 1 in hepatic cell carcinoma
  • Regulatory act of hypoxia-inducible factor 1 in hepatocellular carcinoma
  • Implications of E2F transcription factors in human primary liver carcinoma
  • Zinc finger homeobox 3 in hepatocellular carcinoma progression
  • Inference of forkhead box M1 in hepatocellular carcinoma
  • Influence of nuclear factor kappa-B transcription factor in hepatocellular carcinoma
  • Conclusions and future perspectives
  • Conflict of interest
  • References
  • Further reading
  • Chapter 12. Association of specificity protein 1 with hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • The specificity protein transcription factor
  • CD147 protein and specificity protein 1
  • Cystathionine γ-lyase
  • Ras guanine nucleotide-releasing protein 1
  • RING1 and YY1 binding protein
  • Noncoding RNA genes regulated by specificity protein 1 that promotes hepatocellular carcinoma
  • Conclusions and future directions
  • Acknowledgment
  • References
  • Chapter 13. Promising biomarkers for liver cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Biomarkers
  • Conclusion
  • Acknowledgment
  • References
  • Chapter 14. Molecular signaling and its role in drug resistance in hepatocellular carcinomas
  • Abstract
  • Abbreviations
  • Introduction
  • Signaling pathways and their significance in drug resistance
  • Cancer stem cells
  • Conclusion
  • Conflict of interest
  • References
  • Chapter 15. Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives
  • Abstract
  • Abbreviations
  • Introduction
  • Current therapy for hepatocellular carcinoma
  • Molecular drug targets
  • Antiangiogenic factors
  • Anti-epidermal growth factor receptor inhibitors
  • Mammalian target of rapamycin pathway inhibitor
  • Pathway associated with multidrug resistance
  • Cancer stem cells
  • Tumor microenvironment
  • Therapeutic aspects (overcoming multidrug resistance)
  • Conclusion and future perspectives
  • References
  • Chapter 16. Proliferative signaling pathways in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Significant targeting pathways in hepatocellular carcinoma
  • Conclusions and future perspectives
  • Conflict of interest
  • References
  • Further reading
  • Chapter 17. Targeting angiogenesis in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Antiangiogenic treatment for hepatocellular carcinoma
  • Imaging investigations for angiogenesis
  • Conclusion
  • Conflict of interest
  • Funding
  • References
  • Chapter 18. Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Various biomarkers known for hepatocellular carcinoma
  • Alpha-fetoprotein and lectin-bound alpha fetoprotein 3
  • Prothrombin induced by vitamin K absence II or des-γ-carboxy prothrombin
  • The GALAD model
  • Glypican 3
  • Osteopontin
  • Cystatin B
  • Golgi protein 73
  • Midikines
  • Alpha-L-fucosidase
  • Cytokeratin 19
  • Circulating tumor cells
  • Squamous cell carcinoma antigen
  • Heat shock protein
  • Transcribed ultraconserved region element 338
  • MicroRNAs
  • Transforming growth factor beta
  • Tumor-specific growth factor
  • Epidermal growth factor receptor
  • Hepatocyte growth factor
  • Diagnostic imaging
  • Ultrasound
  • CT scan and MRI scan
  • Next-generation sequencing analysis in hepatocellular carcinoma
  • Gut microbe markers
  • Conclusions
  • References
  • Further reading
  • Chapter 19. Updates on the staging and treatment of hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Staging
  • Treatment
  • Barcelona Clinic Liver Cancer stage 0
  • Barcelona Clinic Liver Cancer stage A (early stage)
  • Barcelona Clinic Liver Cancer stage B (intermediate stage)
  • Barcelona Clinic Liver Cancer stage C (advanced stage)
  • Barcelona Clinic Liver Cancer stage D (terminal stage)
  • Prognostic factors
  • Summary
  • Acknowledgment
  • References
  • Chapter 20. ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy
  • Abstract
  • Abbreviations
  • Introduction
  • Reactive oxygen species biology
  • Reactive oxygen species mediates liver carcinogenesis
  • Reactive oxygen species-mediated cellular pathways
  • Reactive oxygen species in hepatocellular carcinoma therapy
  • Conclusion
  • Acknowledgment
  • Conflict of interest
  • Funding
  • References
  • Chapter 21. Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options
  • Abstract
  • Abbreviations
  • Introduction
  • Signaling factors and pathways implicated in hepatocellular carcinoma
  • Therapeutic options in hepatocellular carcinoma
  • Future prospects
  • Conclusion
  • References
  • Chapter 22. LKB1/STK11-mediated signal transduction in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Liver kinase B1 as a regulator of hepatocellular carcinoma progression
  • Mechanism of liver kinase B1 signaling in hepatocellular carcinoma
  • Adenosine monophosphate–activated protein kinase as the downstream signaling mediator of liver kinase B1
  • Therapeutic strategies
  • Conclusion
  • Acknowledgments
  • References
  • Index

Product details

  • No. of pages: 398
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: April 1, 2022
  • Imprint: Academic Press
  • Hardcover ISBN: 9780323988070
  • eBook ISBN: 9780323993654

About the Editors

Ganji Nagaraju

Dr. Nagaraju GP is a faculty member in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. Dr. Nagaraju received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 70 research papers in highly reputed International journals and has presented more than 50 abstracts at various national and international conferences. Dr, Nagaraju is author and editor of several published books including 1. Role of Tyrosine Kinases in Gastrointestinal Malignancies, 2. Role of Transcription Factors in Gastrointestinal Malignancies and 3. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju is an associate member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

Affiliations and Expertise

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA

Ramakrishna Vadde

Dr Vadde Ramakrishna is Assistant Professor at the Department of Biotechnology & Bioinformatics, Yogi Vemana University, India. He obtained his MSc and PhD, both in Biochemistry, from Sri Krishnadevaraya University, Anantapur, India, and subsequently received a DBT CREST Award to pursue advanced training in cancer research at Pennsylvania State University and Colorado State University, USA. He is currently using in vitro, in vivo and in silico models to explore the role of dietary bioactive compounds in both the development and prevention of cancer through a ‘polypharmacology’ approach. He has published over 90 research papers in prominent international journals and has presented more than 40 papers at national and international conferences. He serves as an editorial board member for several international journals, and is an Associate Fellow of Andhra Pradesh Academy of Sciences.

Affiliations and Expertise

Assistant Professor, Department of Biotechnology and Bioinformatics, Yogi Vemana University, India

Ratings and Reviews

Write a review

There are currently no reviews for "Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2"